JP2021521817A5 - - Google Patents

Info

Publication number
JP2021521817A5
JP2021521817A5 JP2020559369A JP2020559369A JP2021521817A5 JP 2021521817 A5 JP2021521817 A5 JP 2021521817A5 JP 2020559369 A JP2020559369 A JP 2020559369A JP 2020559369 A JP2020559369 A JP 2020559369A JP 2021521817 A5 JP2021521817 A5 JP 2021521817A5
Authority
JP
Japan
Prior art keywords
region
fusion protein
cells
immunoglobulin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559369A
Other languages
English (en)
Japanese (ja)
Other versions
JP7485368B2 (ja
JP2021521817A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2019/005096 external-priority patent/WO2019209078A1/ko
Publication of JP2021521817A publication Critical patent/JP2021521817A/ja
Publication of JP2021521817A5 publication Critical patent/JP2021521817A5/ja
Application granted granted Critical
Publication of JP7485368B2 publication Critical patent/JP7485368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559369A 2018-04-26 2019-04-26 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物 Active JP7485368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0048343 2018-04-26
KR20180048343 2018-04-26
PCT/KR2019/005096 WO2019209078A1 (ko) 2018-04-26 2019-04-26 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Publications (3)

Publication Number Publication Date
JP2021521817A JP2021521817A (ja) 2021-08-30
JP2021521817A5 true JP2021521817A5 (enExample) 2022-04-19
JP7485368B2 JP7485368B2 (ja) 2024-05-16

Family

ID=68293649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559369A Active JP7485368B2 (ja) 2018-04-26 2019-04-26 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物

Country Status (6)

Country Link
US (1) US11820801B2 (enExample)
EP (1) EP3792276A4 (enExample)
JP (1) JP7485368B2 (enExample)
KR (3) KR102194644B1 (enExample)
CN (1) CN112041333B (enExample)
WO (1) WO2019209078A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019309472A1 (en) * 2018-07-24 2021-03-18 Good T Cells, Inc. Composition for preventing or treating immune-related diseases
EP3943107A4 (en) * 2019-03-20 2022-12-07 Good T Cells, Inc. COMPOSITION FOR THE PREVENTION OR TREATMENT OF BRAIN AND NERVOUS SYSTEM DISEASES
CN114929733A (zh) * 2019-11-08 2022-08-19 古德T细胞有限公司 调节性t细胞表面抗原的表位和与其特异性结合的抗体
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
CN122161853A (zh) * 2023-09-06 2026-06-05 古德T细胞有限公司 经亲和力成熟的新型抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EP1907582B1 (en) * 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
KR101847523B1 (ko) 2011-01-24 2018-05-28 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
JP6404349B2 (ja) 2013-07-30 2018-10-10 インダストリー−アカデミック コーポレーション ファウンデーション，ヨンセイ ユニバーシティ サクサチリン−Ｆｃ融合タンパク質及びその用途
AU2019309472A1 (en) * 2018-07-24 2021-03-18 Good T Cells, Inc. Composition for preventing or treating immune-related diseases

Similar Documents

Publication Publication Date Title
JP7485368B2 (ja) 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物
CN116096897A (zh) 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途
KR102652664B1 (ko) 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
JPH04501719A (ja) ポリペプチド
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
EA029300B1 (ru) Антитело к связанному с мембраной человеческому карциноэмбриональному антигену, его получение и применение
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
CN110028584A (zh) 针对egfr蛋白和met蛋白的双特异性抗体
EP4467567A1 (en) Anti-cd70 nanoantibody and use thereof
KR20180117067A (ko) Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
KR20210056280A (ko) 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
KR20250101988A (ko) 면역체크포인트 억제제 저항성 암의 예방, 개선 또는 치료용 조성물
CN117255806A (zh) 结合trop2的抗体及其用途
CN121175410A (zh) TrkA抗体及其用途
CN110799211B (zh) 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
JP2007527232A (ja) Ｎｏｇｏ−ａ結合分子およびその医薬的使用
CN115947855B (zh) 抗cd24抗体的制备及其用途
EP4265269A1 (en) Use of taci protein
KR20130057959A (ko) 항 ｈｅｒ2 단일클론항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
EP4613774A1 (en) Single domain antibody targeting human ror1
TW202602928A (zh) 程序性死亡配體1(pd-l1)嵌合抗原受體及其應用
WO2025099324A1 (en) Antibodies against cd44
WO2023026881A1 (ja) 抗ｐｄ－１シグナルペプチド抗体とその利用
WO2025119330A1 (zh) 氨基酸接头结合分子及其用途